Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Outcomes Studies Are Key To Validating Metabolic Syndrome As A Disease

Executive Summary

European regulators have indicated that providing data from outcomes trials would be the best way to validate metabolic syndrome as a treatable condition, according to RenaSci Consultancy Director David Heal

You may also be interested in...



Novartis’ Outcome Program May Prove Galvus A GLORIOUS First-Line Therapy

Novartis hopes to establish Galvus as a treatment for use in early stage type 2 diabetes through a program of outcomes trials for the dipeptidyl peptidase IV inhibitor

Novartis’ Outcome Program May Prove Galvus A GLORIOUS First-Line Therapy

Novartis hopes to establish Galvus as a treatment for use in early stage type 2 diabetes through a program of outcomes trials for the dipeptidyl peptidase IV inhibitor

Metabolic Syndrome Reimbursement Forecast: Outlook Remains Cloudy

In the near term, the best prospect for establishing a favorable reimbursement climate for metabolic syndrome may be to focus on treating comorbidities

Related Content

UsernamePublicRestriction

Register

PS047071

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel